Is Tilray a good company to invest?

Is TLRY stock a good buy?

Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.

Is Tilray a profitable company?

Tilray delivered a big surprise with its first quarterly update after merging with Aphria — a profit. The company announced net income of $33.6 million, or $0.18 per share. That was a huge improvement from the net loss of $84.3 million, or $0.39 per share, in the prior-year period.

Is Tilray a good long term investment?

But in spite of the indices setting records, there are some stocks lagging now. … Cannabis in general is a sector struggling of late. Tilray (NASDAQ:TLRY) stock has been in a downward spiral since February.

Is Tilray undervalued?

Overall, given its profitability, return to growth, solid domestic foothold, and rising international sales, Tilray is a fantastic stock to buy, especially after year-long dips in the sector. It’s somewhat undervalued at the moment at just 8.4 times revenue.

Is ACB a buy or sell?

For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%. A yield of 8.57% also means 8.57 cents of earnings for $1 of investment.

Momentum Scorecard. More Info.

IT IS INTERESTING:  Question: How does a shareholder work?
Zacks Rank Definition Annualized Return
1 Strong Buy 25.60%
2 Buy 19.21%
3 Hold 10.85%
4 Sell 6.62%

Is APHA a buy or sell?

Aphria has received a consensus rating of Hold. The company’s average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.

Why is Tilray dropping?

Shares of Tilray were down after the company reported a wider-than-expected net loss in the fourth quarter despite a beat in revenue.

What happened to Tilray?

After Tilray’s (TLRY) shareholders voted in favor of the proposed merger Aphria (APHA) last Friday, the two cannabis companies announced today the completion of the transaction.

Is Tilray a Canadian company?

Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States with primary operations headquartered in Toronto, Ontario. Tilray also has operations in Australia, New Zealand, Germany, Portugal, and Latin America.

What is the future of HEXO?

The 10 analysts offering 12-month price forecasts for Hexo Corp have a median target of 5.23, with a high estimate of 9.60 and a low estimate of 2.18. The median estimate represents a +113.47% increase from the last price of 2.45.